Inscripta raises $55.5M to advance gene-editing tech

Inscripta raises $55.5M to advance gene-editing tech

BOULDER -- Inscripta , a leading gene-editing technology company, announced it closed a $55.5 million Series C funding round led by Merieux Developpement and Paladin Capital Group. ... Read More

Wednesday February 28, 2018 0 comments Tags: Boulder, Inscripta, Dr. Kevin Ness, gene editing

Muse bio appoints John Stuelpnagel chairman of board of directors

Muse bio appoints John Stuelpnagel chairman of board of directors

BOULDER -- Muse bio , a privately-held company leading the development of next-generation genome engineering capabilities, announced Dr. John Stuelpnagel , co-founder, first CEO and former COO... Read More

Tuesday May 16, 2017 0 comments Tags: Boulder, Muse bio, John Stuelpnagel, Dr. Kevin Ness, ForgeCraft

Muse bio secures $23M Series B funding led by Venrock investor group

Muse bio secures $23M Series B funding led by Venrock investor group

BOULDER -- Muse bio , a privately-held company leading the development of next-generation genome engineering capabilities, today announced completion of a$23 millionSeries B financing. The... Read More

Tuesday February 28, 2017 0 comments Tags: Boulder, Muse bio, Venrock, Bryan Roberts, Dr. Kevin Ness, ForgeCraft

Muse bio appoints Kevin Ness new company CEO

Muse bio appoints Kevin Ness new company CEO

BOULDER -- Muse bio , a privately-held company leading the development of next-generation genome engineering technologies, announced Dr.Kevin Ness has been appointed CEO and a member of the... Read More

Friday December 9, 2016 0 comments Tags: Muse bio, Boulder, Dr. Kevin Ness, Ryan Gill